title: [Peripheral T-cell lymphomas without primary skin involvement. An anatomicoclinical study of 29 consecutive cases].
abstract: BACKGROUND
  To analyze peripheral non-cutaneous T-cell lymphomas (NC-TCL) and to test the significance of the IPI.
  
  
  METHODS
  Twenty-nine consecutive patients diagnosed with NC-TCL according to the REAL classification.
  
  
  RESULTS
  At diagnosis were common: B symptoms (21%), stage III/IV (55%), high LDH level (55%) and extranodal involvement (79%). Twelve (48%) patients achieved complete remission. The IPI identified groups of patients with different response to therapy and survival.
  
  
  CONCLUSIONS
  NC-TCL with high or high-intermediate IPI had a short survival if treated with CHOP.
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona. 28609ass@comb.es
authors.forename: A
authors.initials: A
authors.lastname: Salar
authors.forename: A
authors.initials: A
authors.lastname: Fernández de Sevilla
authors.forename: V
authors.initials: V
authors.lastname: Romagosa
authors.forename: A
authors.initials: A
authors.lastname: Domingo-Claros
authors.forename: E
authors.initials: E
authors.lastname: González-Barca
authors.forename: A
authors.initials: A
authors.lastname: Grañena
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone